Autologous Haematopoietic Stem-cell Transplantation in Patients with High Risk Neuroblastoma in the Valle del Lili Foundation Hospital, Cali, Colombia
DOI:
https://doi.org/10.35509/01239015.206Keywords:
Haematopoietic Stem Cell Transplantation, Neuroblastoma, Chemotherapy, Radiotherapy, HistopathologyAbstract
Objective: Describe the experience in the management of patients diagnosed with high-risk neuroblastoma treated with autologous haematopoietic stem cell transplantation at the Valle de Lili Foundation Hospital.
Patients and Methods: A series of cases of patients with a diagnosis of high-risk neuroblastoma who received an autologous haematopoietic stem cell transplantation between 2001 and 2015.
The endpoints of this study were: overall survival, event-free survival, platelet and neutrophil graft time and the cumulative incidence of venous-occlusive disease. A descriptive statistical analysis was performed for all the variables considered in the analysis and for the selected subgroups. Survival analysis was performed using the Kaplan-Meier method.
Results: A total of 15 patients diagnosed with high risk neuroblastoma received an autologous haematopoietic stem cell transplantation between 2001 and 2015. Overall survival at 3 and 5 years was 55%, and the event-free survival was 47%. 14/15 patients grafted Neutrophils grafted between day 8 and 19 post-transplant in 14/15 patients, with platelet graft between days 9 and 91 days. Hepatic venous-occlusive disease was observed in 2/15 patients as toxicity to conditioning chemotherapeutic drugs. At the time of the last follow-up, 10/15 patients remained alive, 8 of whom had no clinical and/or para-clinical evidence of the disease. Of the 5/15 patients that died, 2 were due to transplant toxicity in the first 100 days, and 3 due to disease progression.
Conclusion: We conclude that autologous haematopoietic stem cell transplantation is a viable alternative as a treatment in our setting for patients with high-risk neuroblastoma, and has contributed to improve survival in this group of patients.
Author Biographies
Diego Medina, Universidad Icesi
Unidad de Trasplante de Médula Ósea, Fundación Valle del Lili,Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia
Luisa F. Martínez, Universidad Icesi
Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia
Diana M. Dávalos, Fundación Valle del Lili
Facultad de Ciencias de la Salud, Universidad Icesi, Centro de Investigaciones Clínicas, Fundación Valle del Lili, Cali, Colombia
Eliana Manzi, Fundación Valle del Lili
Centro de Investigaciones Clínicas, Fundación Valle del Lili, Cali, Colombia
María C. Rosales, Fundación Valle del Lili
Centro de Investigaciones Clínicas, Fundación Valle del Lili, Cali, Colombia
References
Yaris N, Mandiracioglu A, Büyükpamukcu M. Childhood cancer in developing countries. Pediatr Hematol Oncol. 2004;21:237-53.
https://doi.org/10.1080/08880010490276971
Lanzkowsky P, Jeffrey Lipton J, Fish J. Manual of pediatric hematology and oncology. 6th Edition Academic Press; 2016.
Registro Poblacional de Cáncer de Cali. Sistema de vigilancia epidemiológica de cáncer pediátrico para la ciudad de Cali [internet]. Cali, Colombia: Universidad del Valle; 2010. Disponible en: http://rpcc.univalle.edu.co/Estadisticas_uicc/Estadisticas/index.php?accion=seleccionar_estadistica&categoria=4
Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11:1466-77.
https://doi.org/10.1200/JCO.1993.11.8.1466
Lacayo N, Davis K. Pediatric Neuroblastoma Treatment & Management. Medscape; 2015. Disponible en: http://emedicine.medscape.com/article/988284-treatment
Matthay KK, Villablanca JG, Seeger RC. Treatment of highrisk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow trasplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999;341:1165-73.
https://doi.org/10.1056/NEJM199910143411601
Kushner BH, Modak S, Kramer K, Basu EM, Roberts SS, Cheung NK. Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature. Cancer. 2013;119:665-71.
https://doi.org/10.1002/cncr.27783
Hartmann O, Valteau-Couanet D, Vassal G, Lapierre V, Brugières L, Delgado R, et al. Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: a multivariate analysis in 218 patients treated in a single institution. Bone Marrow Transplant. 1999;23:789-95.
https://doi.org/10.1038/sj.bmt.1701737
Valteau-Couanet D, Le Deley MC, Bergeron C, Ducassou S, Michon J, Rubie H, Le Teuff G, et al. Long-term results of the combination of the N7 induction chemotherapy and the busulfan-melphalan high dose chemotherapy. Pediatr Blood Cancer. 2014;61:977-81,
https://doi.org/10.1002/pbc.24713
Vassal G, Michel G, Espérou H, Gentet JC, Valteau-Couanet D, Doz F, et al. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring. Cancer Chemother Pharmacol. 2008;61:113-23.
https://doi.org/10.1007/s00280-007-0455-2
Peuchmaur M, d'Amore ES, Joshi VV, Hata J, Roald B, Dehner LP, et al. Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular. J Oncology Journal. 2003;98:2274-81.
https://doi.org/10.1002/cncr.11773
Parikh NS, Howard SC, Chantada G, Israels T, Khattab M, Alcasabas P, et al. CLINICAL PRACTICE GUIDELINES SIOP-PODC Adapted Risk Stratification and Treatment Guidelines: Recommendations for Neuroblastoma in Low- and Middle-Income Settings. Pediatr Blood Cancer. 2015;62:1305-16.
https://doi.org/10.1002/pbc.25501
Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, et al. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol. 2013;14:999-1008.
https://doi.org/10.1016/S1470-2045(13)70309-7
Gomez S, Martinez M, Schuttenberg V, Cuello F, Costa A, Fomisano S, Fernandez R. Trasplante autologo (ATPH) de progenitores hematopoyéticos en niños con neuroblastoma. Servicio de hematología Hospital de niños de la plata. Revista Argentina de Hematología. 2005;9:82.
Guía de tratamiento Neuroblastoma alto riesgo 2014. Sociedad Argentina de Hemato-Oncología Pediátrica (SAHOP), Grupo de América Latina de Oncología Pediátrica (GALOP). Hospital de pediatria Prof. Dr. Juan P. Garrahan.
Proust-Houdemont S, Pasqualini C, Blanchard P, Dufour C, Benhamou E, Goma G, et al. Busulfan-melphalan in high-risk neuroblastoma: the 30-year experience of a single institution. Bone Marrow Transplant. 2016;51:1076-81,
https://doi.org/10.1038/bmt.2016.75
Yalc¸in B, Kremer LCM, van Dalen EC. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma. Cochrane Database Syst Rev. 2015:CD006301,
https://doi.org/10.1002/14651858.CD006301.pub4
Kushner BH, Ostrovnaya I, Cheung IY, Kuk D, Modak S, Kramer K, et al. Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin. Oncotarget. 2016;7:4155-66,
https://doi.org/10.18632/oncotarget.6393
Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol. 2009;27:1007-13, Epub 2009 Jan 26.
https://doi.org/10.1200/JCO.2007.13.8925
Park JR, Kreissman SG, London WB, Naranjo A, Cohn SL, Hogarty MD, et al. A phase III randomized clinical trial (RCT) of tandem myeloablative autologous stem cell transplant (ASCT) using peripheral blood stem cell (PBSC) as consolidation therapy for high-risk neuroblastoma (HR-NB): A Children's Oncology Group (COG) study. J Clin Oncol. 2016;34 suppl; abstr-LBA3.
How to Cite
Downloads
Downloads
Published
Issue
Section
License
Todos los derechos reservados.
